Eli Lilly and Company (NYSE:LLY), a US-based pharmaceutical company, announced on Friday that it has named Mary Lynne Hedley, PhD as its new director effective 15 May 2022.

Dr Hedley is to serve both the Science & Technology Committee and the Ethics and Compliance Committee.

Dr Hedley is an immunologist and cancer cell biologist and has served as a senior scientific fellow at the Broad Institute of MIT and Harvard. She has also worked as director, president, and chief operating officer at TESARO, Inc, and has served as executive vice president and chief science officer of Abraxis Bioscience, Inc.